Genzyme Biosurgery/Guidant
This article was originally published in The Gray Sheet
Executive Summary
Cross-license agreement between the firms covers certain patents for products used in "beating-heart" bypass procedures. Genzyme will make a one-time license fee payment to Guidant and pay ongoing royalties for sale of the products. Genzyme President Duke Collier said: "Access to Guidant's intellectual property provides us the opportunity to continue the success of our current off-pump line," which includes the Immobilizer...